Effect of Fentanyl on Main Opioid Receptor (OPRM1) on Human Granulosa Cells.

Effect of Fentanyl on Expression of Main Opioid Receptor (OPRM1) on Human Granulosa Cells During Ultrasound-guided Transvaginal Oocyte Retrieval.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03248076

Enrollment

Registered

2017-08-14

Start date

2017-04-01

Completion date

2018-10-10

Last updated

2017-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use, Stress Reaction

Brief summary

Opioids is known that produce not only analgesia but also hyperalgesia through activation of central glutaminergic system-GABA. At the same time, recently it was found that the main opioid receptor (OPRM1) is present on human granulosa cells and exogenous opiates and their antagonists can influence granulosa cell vascular endothelial growth factor (VEGF) production via OPRM1, causing ovarian hyperstimulation syndrome. This study aims to investigate if a single exposure to opioids is enough to produce activation of stress mechanism during oocyte retrieval.

Detailed description

The main opioid receptor (OPRM1) is present on human granulosa cells and exogenous opiates and their antagonists can influence granulosa cell vascular endothelial growth factor (VEGF) production via OPRM1, causing ovarian hyperstimulation syndrome. This study aims to investigate if a single exposure to opioids is enough to produce activation of stress mechanism during ultrasound-guided oocyte retrieval. It will be measured the level of cortisone before and 15min after iv administration of fentanyl on blood and on oocyte fluid.

Interventions

DRUGFentanyl Citrate

1γ/Kg fentanyl

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 32 Years

Healthy volunteers

Yes

Inclusion criteria

* American Physical Status I-III, BMI\<30,

Exclusion criteria

* Heart failure * hepatic failure, hepatitis, * drug abuse * receiving b blockers * receiving b agonists (even bronchodilators)

Design outcomes

Primary

Measure	Time frame	Description
fentanyl	15 minutes	fentanyl on blood sample and oocyte fluid

Secondary

Measure	Time frame	Description
cortisone	15 min	cortisone on blood sample and oocyte fluid

Countries

Greece

Contacts

Primary ContactIrene Asouhidou, MD, PhD

iasouh@aol.com00302310999321

Backup ContactEvaggelos Papanikolaou, MD, PhD

drvagpapanikolaou@yahoo.gr00302310424294

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026